Claudio Vernieri
Claudio Vernieri is an expert in Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori (Italy). As of October 2026, ScienceLeadR ranks Claudio Vernieri in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Claudio Vernieri has authored 226 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 14 of them ongoing. SLR score: 1,344 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Surgery - Public Health - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 226
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Observation of a B_{c}^{*+} Meson with the ATLAS Detector. PMID 42886898 — physics | Phys Rev Lett | 2026 | 0 |
| Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study. PMID 42872060 — hormones, therapeutics | EClinicalMedicine | 2026 | 0 |
| Combination of ATLAS and CMS Searches for Higgs Boson Pair Production at sqrt[s]=13 TeV. PMID 42854147 — physics | Phys Rev Lett | 2026 | 0 |
| Measurements of Z-Boson Pair Entanglement in Decays of Higgs Bosons at the ATLAS Experiment. PMID 42789880 — research design, physics | Phys Rev Lett | 2026 | 2 |
| Evidence of ZZγ Production with the ATLAS Detector. PMID 42726943 — physics | Phys Rev Lett | 2026 | 1 |
Clinical Studies 22
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
14 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Advanced Breast Cancer 2025-523013-28-00 — fulvestrant, safety, breast neoplasms, neoplasms, hormones, breast, chromosomes, mutation | Phase 2 | Recruiting | 2026 |
| A proof of concept study to evaluate treatments efficacy by monitoring Minimal Residual Disease using ctDNA in HR positive HER2 negative early breast cancer population 2023-505661-89-00 — epidermal growth factor, growth, breast neoplasms, neoplasms, hormones, proof of concept study, receptors, growth factor, breast, neoplasm, residual, therapeutics | Phase 2 | Recruiting | 2024 |
| A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine Versus Tucatinib in Combination with Trastuzumab and Capecitabine in People with Locally Advanced or Metastatic Breast Cancer that is HER2 Positive 2025-524498-17-00 — blood-brain barrier, epidermal growth factor, growth, safety, blood, breast neoplasms, brain, neoplasms, central nervous system, neoplasm metastasis, receptors, growth factor, breast, nervous system, capecitabine, trastuzumab | Phase 2/Phase 3 | Not yet recruiting | 2026 |
| An Open label Randomized Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician s Choice in Hormone Receptor positive HER2 negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA Breast04) 2025-520582-51-00 — breast neoplasms, neoplasms, respect, hormones, breast, therapeutics | Phase 3 | Active not recruiting | 2025 |
| Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer 2024-519655-28-00 — lymph nodes, breast neoplasms, neoplasms, multiple chronic conditions, neoplasm micrometastasis, lymph, breast, therapeutics, women | Phase 3 | Recruiting | 2026 |
LeadR Networks
Main global connection map